Russell G. Greig, Ph.D
Chairman of the Board
Russell G. Greig, Ph.D. worked at GlaxoSmithKline for three decades, most recently as President of SR One, GlaxoSmithKline’s corporate venture group. Prior to joining SR One, he served as President of GlaxoSmithKline’s Pharmaceuticals International from 2003 to 2008 as well as on the GlaxoSmithKline corporate executive team. Currently, Dr. Greig serves as Chairman of Merus and MedEye Solutions in the Netherlands, eTheRNA in Belgium, Sanifit in Spain and Horama in France He was previously Chairman of Ablynx in Belgium (acquired by Sanofi, France), Isconova in Sweden (acquired by Novavax, United States), Novagali in France (acquired by Santen, Japan) and Syntaxin in the United Kingdom (acquired by Ipsen, France), as well as board member of TiGenix in Belgium (acquired by Takeda, Japan).
Gbola Amusa, MD
Dr. Gbola Amusa is Partner, Director of Research and Head of Healthcare Research at Chardan.. Dr. Amusa joined Chardan at the end of 2014 to focus on identifying companies that will generate exceptionally high long-term investment returns by creating shared value for society. Dr. Amusa was previously Managing Director, Head of European Pharma Research, and Global Pharma & Biotech Coordinator at UBS, where he oversaw 25 analysts, and ultimately finished as the #1 ranked European pharma analyst in the Institutional Investor (II) Survey. Prior to UBS, Dr. Amusa was a Senior Research Analyst and Head of European Pharma research at Sanford Bernstein. He started his career in finance at Goldman Sachs as an Associate in the Healthcare Investment Banking Group, where he worked on large transactions including the Amgen/Immunex merger. Additionally, Dr. Amusa was previously a Healthcare Finance & Strategy Consultant working with governments, companies, leading foundations and think tanks. Dr. Amusa’s views on healthcare have been cited by socially responsible investing (SRI), ESG and sustainability organizations like FSG/Shared Value Initiative, GMI Ratings and the ATM Index. Dr. Amusa earned his BSE with honors in biomedical engineering from Duke University, an MD from Washington University Medical School, and his MBA (GPA 4.0/4.0) from the University of Chicago, Booth School of Business.
Jonas Grossman is President of Chardan where he oversees the firm’s global capital markets initiatives including deal origination, syndication and secondary market sales and trading. Previously, Mr. Grossman worked at Ramius Capital Group, LLC, a global multi-strategy hedge fund where he served as Vice President and Head Trader from 2001 to 2003. He began his investment career in the cash equities business working at Aegis Capital Corp and Windsor Capital Advisor from 1999 to 2000. Mr. Grossman received a B.A. in Economics from Cornell University and an M.B.A. from the Leonard N. Stern School of Business at New York University. He also studied at the London School of Economics.
Alan Moses, MD
Alan Moses, M.D., was co-founder and co-director of the Clinical Investigator Training Program at Beth Israel Deaconess-Harvard Medical School-MIT. Dr. Moses served as Senior Vice President and Chief Medical Officer of the Joslin Diabetes Center in Boston. He was appointed Professor of Medicine at Harvard Medical School. Over the course of 14 years at Novo Nordisk, Dr. Moses served in multiple roles, rising to the position of Senior Vice President and Global Chief Medical Officer. During his tenure there, Dr. Moses provided medical support to regulatory filings for the approval of 11 successful Novo Nordisk products. Dr. Moses earned his M.D. from the Washington University School of Medicine in St. Louis, worked at the National Institutes of Health and completed subspecialty clinical training in Endocrinology at Tufts New England Medical Center.
Paul Sekhri is President and Chief Executive Officer of the gene editing company eGenesis. He has served as President and Chief Executive Officer of Lycera Corp., and as Executive Vice President of Business Development and Chief Strategy Officer for Teva Pharmaceuticals. Mr. Sekhri has served as President and Chief Business Officer of ARIAD Pharmaceuticals and was Senior Vice President and Head of Global Search and Evaluation, M&A at Novartis. He also was an Operating Partner at TPG Biotech, where he oversaw the health and success of 52 companies within the TPG Biotech portfolio. Mr. Sekhri completed graduate work at the University of Maryland School of Medicine and received his B.S. from the University of Maryland, College Park.
Ms. Sullivan most recently served as Chief Financial Officer for Compass Therapeutics, LLC. Prior to Compass, Ms. Sullivan served as the Senior Vice President of Finance for Biogen, Inc., where she spearheaded Biogen’s Financial Planning & Analysis, Corporate Tax, and Corporate Finance groups, which includes ownership of long-range planning, capital allocation projects and the financial aspects of Mergers & Acquisitions/Business Development. Prior to that, Ms. Sullivan was the Vice President of Tax for Biogen, Vice President Tax for EMD Serono and the Vice President of Tax North America at Merck KgaA. Ms. Sullivan serves also on the Boards of resTORbio and Solid Biosciences.
Jonathan Eitan Solomon
CEO and Board Member
Prior to his role in BiomX, Mr. Solomon was a co-founder, president, and CEO of ProClara (formerly NeuroPhage), which is pioneering an approach to treating neurodegenerative diseases. Under his leadership, the company raised more than $100 million and launched an ongoing clinical trial related to Alzheimer’s disease. Prior to that, he was selected to participate in the elite Israeli Defense Forces ‘Talpiot’ program, graduated as class valedictorian, and served for 10 years in a classified military unit. Mr. Solomon holds a B.Sc. magna cum laude in Physics and Mathematics from the Hebrew University, an M.Sc. summa cum laude in Electrical Engineering from Tel Aviv University, and an M.B.A. with honors from the Harvard Business School.